For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Glucagon is a metabolic hormone secreted by the pancreas that raises blood glucose levels by causing the liver to rapidly convert glycogen (the stored form of glucose) into glucose, which is then released into the bloodstream. Glucagon and insulin are two critical hormones in a glycemic control system that keeps blood glucose at the right level in healthy individual. Glucagon is a medicine which used to treat severe low blood sugar (hypoglycemia). Glucagon works by telling your body to release sugar (glucose) into the bloodstream to bring the blood sugar level back up.
Scope of the Report:
The classification of glucagon includes inject glucagon and nasal glucagon, and now almost all the product is the type of injection. In 2018, Eli Lilly will launch the nasal glucagon in the market.
Glucagon is widely used in emergency kits, general use, diagnostic & motility, cardiogenic shock and other field. The most proportion of Glucagon is emergency kits, which is about 335 in2016.
North America is the largest consumption place, with a consumption market share nearly 41% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 25%.
Market competition is intense. Novo Nordisk, Eli Lilly, Fresenius Kabi, Torrent Labs, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Glucagon is expected to grow at a CAGR of roughly 6.2% over the next five years, will reach 620 million US$ in 2024, from 430 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Glucagon in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Novo Nordisk
- Eli Lilly
- Fresenius Kabi
- Torrent Labs
- Taj Pharmaceuticals
- Xeris Pharmaceuticals
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Inject Glucagon
- Nasal Glucagon
Market Segment by Applications, can be divided into
- Emergency Kits
- General Use
- Diagnostic & Motility
- Cardiogenic Shock
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Glucagon, with price, sales, revenue and global market share of Glucagon in 2017 and 2018.
Chapter 3, the Glucagon competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Glucagon market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Glucagon sales channel, distributors, customers, research findings and conclusion, appendix and data source.